Literature DB >> 11234876

The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.

J Schindler1, E Sausville, R Messmann, J W Uhr, E S Vitetta.   

Abstract

A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11234876

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Authors:  Christoph Groth; Lenneke F J van Groningen; Tiago R Matos; Manita E Bremmers; Frank W M B Preijers; Harry Dolstra; Christian Reicherts; Nicolaas P M Schaap; Eric H G van Hooren; Joanna IntHout; Rosalinde Masereeuw; Mihai G Netea; John E Levine; George Morales; James L Ferrara; Nicole M A Blijlevens; Ypke V J M van Oosterhout; Matthias Stelljes; Walter J F M van der Velden
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-03       Impact factor: 5.742

Review 2.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

3.  Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.

Authors:  Stefan K Barta; Yiyu Zou; John Schindler; Niraj Shenoy; Tushar D Bhagat; Ulrich Steidl; Amit Verma
Journal:  Leuk Lymphoma       Date:  2012-04-18

4.  A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.

Authors:  John Schindler; Srikanth Gajavelli; Farhad Ravandi; Yumin Shen; Samir Parekh; Ira Braunchweig; Stefan Barta; Victor Ghetie; Ellen Vitetta; Amit Verma
Journal:  Br J Haematol       Date:  2011-07-07       Impact factor: 6.998

5.  A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.

Authors:  Gennaro Riccio; Chiara D'Avino; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2012-12-11       Impact factor: 1.650

6.  Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.

Authors:  Xiao-yun Liu; Laurentiu M Pop; John Schindler; Ellen S Vitetta
Journal:  MAbs       Date:  2012 Jan-Feb       Impact factor: 5.857

7.  Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

Authors:  Chiara D'Avino; Rolando Paciello; Gennaro Riccio; Carmela Coppola; Melina Coppola; Paolo Laccetti; Nicola Maurea; Ronald T Raines; Claudia De Lorenzo
Journal:  Protein Eng Des Sel       Date:  2014-01-12       Impact factor: 1.650

8.  Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.

Authors:  D A Vallera; B J Stish; Y Shu; H Chen; A Saluja; D J Buchsbaum; S M Vickers
Journal:  Gut       Date:  2008-01-25       Impact factor: 23.059

9.  A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.

Authors:  M Borriello; P Laccetti; G Terrazzano; G D'Alessio; C De Lorenzo
Journal:  Br J Cancer       Date:  2011-05-10       Impact factor: 7.640

10.  Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts.

Authors:  Jaime Tomé-Amat; Miriam Olombrada; Javier Ruiz-de-la-Herrán; Eduardo Pérez-Gómez; Clara Andradas; Cristina Sánchez; Leopoldo Martínez; Álvaro Martínez-Del-Pozo; José G Gavilanes; Javier Lacadena
Journal:  Springerplus       Date:  2015-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.